Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mukhtar Shah

Psychiatry Wichita, KS Medical Doctor

NPI 1396763827 CMS profile 108961

1148 S Hillside St, Ste 104, Wichita, KS 67211

Open in the dashboard

General payments

$11,848

692 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mukhtar Shah of Wichita, KS is reported in the CMS Open Payments database as having received $11,848 across 692 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $864 34
2024 General $1,301 67
2023 General $1,954 100
2022 General $2,318 134
2021 General $2,037 142
2020 General $1,775 118
2019 General $1,599 97

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mukhtar Shah
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Mukhtar Shah were reported at $864. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Mukhtar Shah Psychiatry median Middle half National median
2019 $1,599 $184 $59–$605 $163
2020 $1,775 $119 $36–$372 $114
2021 $2,037 $143 $43–$576 $132
2022 $2,318 $153 $50–$590 $149
2023 $1,954 $170 $56–$651 $160
2024 $1,301 $179 $57–$673 $164
2025 $864 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lundbeck LLC $1,284 68 payments
  2. Vanda Pharmaceuticals Inc. $1,203 55 payments
  3. Otsuka America Pharmaceutical, Inc. $1,171 67 payments
  4. Teva Pharmaceuticals USA, Inc. $1,046 56 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $757 42 payments
  6. Neurocrine Biosciences, Inc. $657 60 payments
  7. Alkermes, Inc. $624 31 payments
  8. Sunovion Pharmaceuticals Inc. $581 44 payments
  9. ITI, Inc. $539 29 payments
  10. Neos Therapeutics, LP $521 41 payments
  11. Other $3,465 199 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,655 689 payments
  2. Education $193 3 payments
Products named General payments · program years 2019–2025
  1. REXULTI Psychiatry $1,246 66 payments
  2. FANAPT $1,203 55 payments
  3. HETLIOZ $1,112 50 payments
  4. REXULTI Psychiatry $1,044 58 payments
  5. ARISTADA Cns $624 31 payments
  6. ARISTADA Cns $624 31 payments
  7. TRINTELLIX $603 33 payments
  8. LYBALVI $587 29 payments
  9. LATUDA $581 44 payments
  10. AUSTEDO $554 38 payments
  11. Other $7,893 487 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

2,905

Median for Psychiatry: 574

Drug cost

$77,108

Median for Psychiatry: $27,624

Branded share of claims

19%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 16 $34,155
Quviviq Daridorexant Hcl Brand 15 $6,378
Perphenazine Generic 37 $2,304
Quetiapine Fumarate Generic 184 $2,216
Alprazolam Generic 278 $2,084
Divalproex Sodium Er Divalproex Sodium Brand 39 $1,967
Bupropion Xl Bupropion Hcl Brand 133 $1,939
Duloxetine Hcl Generic 115 $1,921
Venlafaxine Hcl Er Venlafaxine Hcl Brand 179 $1,910
Clozapine Generic 21 $1,898

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$52,072

Medicare's payments for the services billed

Medicare patients

197

Average age 68

Services billed

841

121 women, 76 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 73%
Arthritis 44%
Diabetes 34%
Ischemic heart disease 32%
Chronic kidney disease 28%
COPD 27%
Alzheimer's or dementia 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $240
  • Otsuka America Pharmaceutical, Inc. $44
$284 16 —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $141
$141 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $140
$140 — —
Auvelity
  • Axsome Therapeutics, Inc. $106
$106 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $99
$99 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

692 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Kansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record